Connect with us

Business

Aurora Cannabis reports $87 million loss, aims for positive free cash flow

Published

on

Aurora Cannabis reported a loss of 87 million Canadian dollars ($65 million) for the three months ended March 31, 2023, up slightly from the CA$67.2 million net loss reported in the previous quarter.

However, the Edmonton, Alberta-based company posted positive adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of CA$300,000 for the three months – Aurora’s second straight positive adjusted EBITDA.

The cannabis producer’s net sales amounted to CA$64 million in the third quarter, increasing 4% sequentially from the previous quarter’s CA$61.7 million.

The revenue and adjusted EBITDA figures came in slightly below the consensus among analysts.

Aurora changed its year-end to March 31, so the fiscal year 2023 results comprise only three quarters.

In a conference call with analysts, CEO Miguel Martin said the consecutive positive adjusted EBITDA figures demonstrate that the company’s “business transformation plan” is working.

He said the company’s next financial milestone is generating positive free cash flow, which it aims to achieve before the end of calendar 2024.

Aurora has already saved CA$400 million annually, Martin said, by “rationalizing expenses,” such as closing some facilities, in the past three fiscal years.

The company on Wednesday also announced a plan to achieve an additional CA$40 million in annualized savings.

To that end, Aurora said it is closing its leased facility in Denmark.

“This fiscal year we’re working on taking out a minimum of CA$5 million quarterly from operations, as we eliminate less efficient operations and focus on supplying the globe from our very low cost and high-quality production facilities (in Canada),” Chief Financial Officer Glen Ibbott told analysts.

By category, Aurora’s medical cannabis net revenue fell 4% from the previous quarter to CA$37.9 million.

Martin told analysts that insured patients represent 82% of Aurora’s third-quarter medical cannabis revenue.

“Our industry-leading share remains at about 25%, roughly double that of our closest competitor,” he said during the conference call.

Sales of nonmedical cannabis fell 1% from the previous quarter to CA$14.5 million.

Canada’s recreational market still has challenges, Martin said, citing price compression.

“But we do see spots where you can perform and still make some money – concentrates, pre-rolls and ingestible, which we have had considerable success in,” the CEO said.

“I think we’re a little bit of a ways off where there will be strong economics across all aspects of the rec portfolio, but it’s definitely getting better.

“We see some glimmers of hope with provincial entities such as the (Ontario Cannabis Store) putting in pricing floors. We do see a little bit of rationalizing of pricing, particularly on flower.”

Aurora is among a handful of cannabis producers who have diversified sales outside the industry in recent years.

Plant-propagation revenue in the third quarter represented a significant increase from the second quarter, “as the segment delivers its highest revenue in the last winter and spring months as orders are fulfilled,” Martin said.

Aurora has completed repurposing its 800,000-square-foot Aurora Sky facility in Edmonton for orchid and vegetable propagation.

The company expects to see sales generated from the Sky facility in the final quarter of calendar 2023.

“Once executed, Bevo’s financial contribution could be significant,” Martin said, referencing Aurora’s CA$45 million acquisition of a controlling interest in Bevo last summer.

Langley, British Columbia-based Bevo is a profitable supplier of propagated vegetables and ornamental plants.

“This rapid expansion serves to increase Bevo’s production capability and extends its shipping range to Canada and the United States,” the CEO added.

Plant-propagation revenue rose 62% from the previous quarter to CA$10.7 million in the third and final quarter of Aurora’s 2023 fiscal year.

Aurora shares trade on the Toronto Stock Exchange and Nasdaq.

Source: https://mjbizdaily.com/aurora-cannabis-reports-87-million-loss/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News